Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
59.56
-3.20 (-5.10%)
Mar 10, 2026, 9:37 AM EDT - Market open
Xenon Pharmaceuticals Revenue
In the year 2025, Xenon Pharmaceuticals had annual revenue of $7.50M.
Revenue (ttm)
$7.50M
Revenue Growth
n/a
P/S Ratio
696.14
Revenue / Employee
$20,270
Employees
370
Market Cap
4.95B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.50M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 9.43M | -9.00M | -48.83% |
| Dec 31, 2021 | 18.44M | -13.73M | -42.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.73B |
| Caris Life Sciences | 812.03M |
| Mirum Pharmaceuticals | 521.31M |
| CG Oncology | 4.04M |
| CRISPR Therapeutics AG | 3.51M |
XENE News
- 17 hours ago - Xenon Pharmaceuticals Announces Proposed Public Offering - GlobeNewsWire
- 18 hours ago - Crude Oil Rises Around 4%; Xenon Pharmaceuticals Shares Surge - Benzinga
- 19 hours ago - Xenon Pharmaceuticals Inc. (XENE) Discusses Positive Top Line Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures Transcript - Seeking Alpha
- 21 hours ago - Xenon: Shares Soar On Seizure Data, But Valuation May Be Overcooked - Seeking Alpha
- 1 day ago - Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures - Benzinga
- 1 day ago - Xenon Pharma's epilepsy drug meets main goal in late-stage trial - Reuters
- 1 day ago - Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS) - GlobeNewsWire
- 1 day ago - Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026 - GlobeNewsWire